Research programme: hepatitis B virus therapy - Novita Healthcare

Drug Profile

Research programme: hepatitis B virus therapy - Novita Healthcare

Alternative Names: AM-491; AVX-491

Latest Information Update: 24 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Avexa
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 31 May 2004 Avexa Ltd., has been established as a spin-out of AMRAD's anti-infectives drug portfolio
  • 22 Jan 2003 This programme is still in active development
  • 25 Sep 2000 Preclinical development for Hepatitis B in Australia (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top